

January 07, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Re.: Phase III Clinical Trial of DengiAll® by ICMR and Panacea Biotec - Completion of enrollment of study participants

Dear Sir/Madam,

This is in continuation to our earlier letter dated August 14, 2024, intimating about initiation of Phase III clinical trial of Panacea Biotec Limited's tetravalent dengue candidate vaccine, DengiAll® in India.

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we are now delighted to inform you that enrollment of study participants in context of DengiAll® Phase-III clinical trial has been completed (i.e., 10,335 study participants).

The Company shall continue to monitor each participant, post administration of the Investigational Medicinal Product (i.e., vaccine or Placebo), for a period of two years to examine the efficacy and immunogenicity of the vaccine.

DengiAll® will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027.

This is for your kind information and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for Panacea Biotec Limited

**Ankit Jain
General Manager – Legal and Company Secretary**